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Venous neointimal hyperplasia in polytetrafluoroethylene dial- Hemodialysis vascular access dysfunction is the single
ysis grafts. most important cause of morbidity in the hemodialysis
Background. Vascular access dysfunction is the most impor- population (currently 200,000 and growing at a rate of
tant cause of morbidity and hospitalization in the hemodialysis 7% per annum) [1]. It has been estimated that vascular
population in the United States at a cost of $1 billion per
access dysfunction is responsible for approximately 20%annum. Venous neointimal hyperplasia (VNH) characterized
of all hospitalizations in the end-stage renal disease pop-by stenosis and subsequent thrombosis accounts for the over-
ulation [2] at a cost of $1 billion per annum. The mostwhelming majority of pathology resulting in polytetrafluoro-
ethylene (PTFE) dialysis graft failure. Despite the magnitude common form of vascular access procedure performed
of the problem and the enormity of the cost ($1 billion), there in chronic hemodialysis patients in the United States is
are currently no effective therapies for the prevention or treat- the arteriovenous polytetrafluoroethylene (PTFE) graft,
ment of venous neointimal hyperplasia in PTFE dialysis grafts. comprising as much as 83% of all hemodialysis accesses
Methods. Tissue samples were collected from the graft-vein [3]. The current one-year primary patency rate for PTFEanastomosis of stenotic PTFE grafts during surgical revision.
dialysis grafts is 40 to 50%, with a two-year patency rateSpecimens were graded using standard light microscopy and
of approximately 25% [4, 5]. Graft thrombosis is theimmunohistochemistry for the magnitude of neointimal hyper-
cause of 80% of all vascular access dysfunction, and inplasia and for the expression of specific cell types, cytokines,
and matrix proteins. over 90% of thrombosed grafts, the underlying pathology
Results. VNH was characterized by the (1) presence of is a stenosis either at the venous anastomotic site or in the
smooth muscle cells/myofibroblasts, (2) accumulation of extra- downstream (proximal) vein [6]. Despite the enormity of
cellular matrix components, (3) angiogenesis within the neo- this problem, however, there are currently no effective
intima and adventitia, and (4) presence of an active macro- interventions for either the prevention or treatment of
phage cell layer lining the PTFE graft material. Platelet-derived
venous stenosis in PTFE dialysis grafts [7, 8]. This isgrowth factor (PDGF), basic fibroblast growth factor (bFGF),
probably caused by a lack of knowledge about the patho-and vascular endothelial growth factor (VEGF) were expressed
physiology underlying venous stenoses in PTFE grafts,by smooth muscle cells/myofibroblasts within the venous neo-
especially at a cellular and molecular level [7].intima, by macrophages lining both sides of the PTFE graft,
and by vessels within the neointima and adventitia. Few studies have attempted to analyze the pathology
Conclusions. Our results suggest that macrophages, specific of venous stenosis in PTFE dialysis grafts. Swedberg et al
cytokines (bFGF, PDGF, and VEGF), and angiogenesis within demonstrated that smooth muscle cells and extracellular
the neointima and adventitia are likely to contribute to the matrix (ECM) proteins are important components of
pathogenesis of VNH in PTFE dialysis grafts. Interventions
this lesion [9], while Rekhter et al have shown that thereaimed at these specific mediators and processes may be success-
is a significant amount of angiogenesis within these speci-ful in reducing the very significant human and economic costs
mens [10].of vascular access dysfunction.
Recent studies in a variety of experimental arterial
models of endothelial and smooth muscle injury have
suggested that macrophages, endothelial cells, and smoothKey words: vascular access, hemodialysis access, stenosis, thrombosis,
angiogenesis. muscle cells/myofibroblasts are all involved in the response
to injury that is responsible for the development of neo-Received for publication November 5, 1999
intimal hyperplasia [11, 12]. Potential mediators thoughtand in revised form September 22, 2000
Accepted for publication January 11, 2001 to play a role in this process include basic fibroblast
growth factor (bFGF) [13], platelet-derived growth factorÓ 2001 by the International Society of Nephrology
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(PDGF) [14], vascular endothelial growth factor (VEGF) Molecules analyzed
[15], and ECM proteins [16]. However, it is not clear The expression of the following cell types, cytokines,
that the mechanisms ascribed to arterial injury also apply and matrix proteins was analyzed in our samples. Table
to venous injury following PTFE graft anastomosis [17]. 1 shows details about the antibodies used.
Therefore, we analyzed the distribution of specific cell Cell types. Specific antibodies recognizing smooth
types, cytokines, and matrix proteins from human vein muscle cells and myofibroblasts [a-smooth muscle actin
(a-SMA) and desmin], endothelial cells [von Willebrandsamples in patients with PTFE graft thrombosis. Cyto-
factor (vWF)], proliferating cells (Ki-67), and a macro-kines and matrix proteins were chosen based on their
phage marker (PGM-1) were used in this study. Weputative involvement in other vascular injury syndromes
chose to examine expression of these cell types in view[11, 12]. Identification of the mediators present in these
of the important role they played in other models offailed grafts may provide insight into potential therapeu-
vascular injury [11]. Of note, SMA and desmin are differ-tic targets for venous stenosis in PTFE dialysis grafts.
entiation markers for cells of a smooth muscle cell phe-
notype [18, 19].
Cytokines. The expression of PDGF-B, bFGF, andMETHODS
VEGF was analyzed based on their documented rolePatients
in the pathogenesis of arterial neointimal hyperplasia
Clinical information was available on 7 of the 11 pa- [11, 20].
tients in our study. Within these constraints, the mean Matrix/structural proteins. Collagen IV, fibronectin,
age of our patients was 62.6 years (range 41 to 85). Six tenascin, and laminin are all ECM proteins. Except for
were African American, and one was Caucasian. Six tenascin, their counter-receptors belong to the integrin
out of seven were male. Type II diabetes mellitus (four family of molecules. ECM proteins play a key role in
patients), hypertension (two patients), and nonrecovery modulating cellular proliferation through feedback
from acute tubular necrosis (1 patient) were the cause mechanisms, and previous studies suggest a role for these
of end-stage renal disease. All seven patients were hyper- molecules in experimental models of neointimal hyper-
tensive. The mean cholesterol level was 167 mg/dL plasia [16, 19, 21].
(range 125 to 187), and the mean triglyceride level was
Antibody specificities296 mg/dL (range 93 to 516). The graft in question was
All of the antibodies used in this study are commer-the first permanent access in all patients. One patient
cially available (Table 1). We have previously docu-had a previous cuffed catheter. The average time be-
mented the specificity of the anticytokine antibodies withtween graft placement and the surgical revision (time of
peptide inhibition studies for the anti–PDGF-B anti-specimen acquisition) was 37 months (8 to 66 months).
body, Western blots against cell extracts known to ex-The average number of thrombotic episodes in this co-
press bFGF, for the anti-bFGF antibody, and a compari-hort was three (range 1 to 6).
son of the staining patterns with two other VEGF
antibodies, for our anti-VEGF antibody [22].Collection of samples
Discarded segments from the venous end of 11 PTFE Immunohistochemistry
grafts were collected at the time of graft revision surgery
A standard automated streptavidin biotin technique
of thrombosed PTFE dialysis grafts. While we tried to
was used (Ventana 320ES automated immunostainer,
obtain upstream graft (just before the graft-vein anasto- Tucson, AZ, USA). Briefly, following deparaffinization
mosis) and downstream (proximal) vein (beyond the and hydration, slides were washed and underwent prote-
graft-vein anastomosis and towards the heart) in each ase digestion (if required for a particular primary anti-
of the samples, this was not always possible because of body). Slides were then incubated with the primary anti-
the surgical constraints associated with refashioning the body for 32 minutes with the biotinylated secondary
thrombosed graft. Excised tissue was fixed in formalin antibody blend (anti-rabbit Ig, anti-mouse IgG, and anti-
and then embedded in paraffin using standard tech- mouse IgM) for eight minutes and with the streptavidin/
niques. The number of tissue blocks from each sample horseradish peroxidase for eight minutes (Table 1). All
varied from one to six. This was dependent on the incubations were performed at 378C with constant move-
amount of graft with attached vein that individual sur- ment and with appropriate washes between each step.
geons were able to obtain at the time of graft revision The slides were then developed with a diaminobenzidine/
surgery. Each block was 3 to 4 mm in thickness. Normal hydrogen peroxide mixture for four minutes, counter-
vein of similar caliber to veins in the forearm was ob- stained with hematoxylin, dehydrated with graduated
alcohol and xylene, and mounted using a xylene-basedtained at the time of multiorgan harvest.
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Table 1. Antibody specificities
Antibody against Source Clone Dilution Epitope recognized
Smooth muscle cells DAKO 1A4 1:200 Terminal decapeptide of a-smooth muscle actin
Endothelial cells DAKO Polyclonal 1:6000 von Willebrand factor
Proliferating cells AMAC Inc. MIB-1 1:50 Ki-67 nuclear antigen in G1, S, G2, M phases
Macrophages DAKO PG-M1 1:50 110 kD glycoprotein encoding the CD68 antigen
Smooth muscle (desmin) DAKO DE-R-11 1:50 18 kD rod piece of the 53 kD intermediate filament desmin
basic FGF Oncogene Polyclonal 1:100 Rabbit polyclonal raised against aa 40–63 of human bFGF
PDGF Santa Cruz Polyclonal 1:125 Raised in rabbits against aa 1-30 at the N terminus of human PDGF-B
VEGF Santa Cruz Polyclonal 1:8 Raised in rabbits against aa 1-20 at the N terminus of human VEGF
Collagen IV Sigma COL-94 1:225 Recognizes an epitope on the a1 and a2 chains
Fibronectin NovoCastra 568 1:750 Cell attachment domain of human fibronectin
Laminin Sigma LAM89 1:2500 Purified human laminin
Tenascin DAKO TN2 1:150 Purified human tenascin; Does not cross-react with fibrinogen
Abbreviations are defined in Appendix.
are shown in Figure 2. Within individual specimens, sepa-
rate scores were given for those samples that contained
PTFE graft (upstream graft) and those that did not
(downstream vein). Thus, in the Results section, when
reference is made to findings at the site of upstream
PTFE graft, it indicates the pattern of staining either at
the graft-vein anastomosis or just before the anastomosis
(Fig. 1, areas B and C; PTFE graft would always be
present in such a sample), while findings that refer to
downstream (proximal) vein indicate the pattern of stain-
ing in the venous segment beyond the graft and towards
the heart (Fig. 1, area A; no PTFE graft would be present
in these samples). Each parameter analyzed (whether
cell type, cytokine, or matrix protein) was assessed at a
number of different sites within the specimen. For exam-
ple, VEGF expression was scored within (1) the adventi-
tial vessels overlying upstream graft and downstreamFig. 1. Diagrammatic representation of the venous anastomosis to
demonstrate how the sections were cut. Maximal neointimal hyperplasia vein, (2) the macrophage/giant cell layer lining both sides
occurred at the site of the graft-vein anastomosis (B) and in the down- of the graft, (3) infiltrating macrophages within the graft,stream vein (A).
and (4) stromal cells (smooth muscle cells/myofibro-
blasts) and microvessels within the neointima of both
upstream graft and downstream vein.medium. A brown color indicated a positive stain. Nega-
tive controls were performed on each run by substituting
Statistical analysesthe primary antibody with a relevant nonspecific immuno-
Although this study was designed essentially as a de-globulin (rabbit polyclonal or mouse monoclonal). In ad-
scriptive analysis, a statistical analysis comparing the ex-dition, positive control tissue (gut, lymph node, and spleen)
pression of specific cell types, cytokines, and matrix pro-was used to document the efficacy of each antibody.
teins in the upstream graft (Fig. 1, areas B and C and
Histologic scoring Table 2) was performed in comparison with the down-
stream vein (Fig. 1, area A and Table 2). This comparisonThe degree of neointimal hyperplasia on hematoxylin
was only made between the same parameter at differentand eosin (H and E) sections and the intensity of immu-
sites. This was done to ensure that the semiquantitativenohistochemical staining for the different cell types, cyto-
score at the two different sites indicated the same level ofkines, and matrix/structural proteins listed above was
expression (for example, in the comparison of adventitialscored by two observers (S.C.H. and P.R.C.) on a semi-
angiogenesis in upstream graft vs. downstream vein, aquantitative scoring scale from 0 (minimal VNH or no
score of 21 indicated the same number of microvesselsexpression) to 51 (significant VNH or intense expres-
at the two sites). The expression of the same cellularsion). Most of our tissue samples had more than one
phenotype at different sites in the specimens was alsosection. Therefore, the section with the maximum score
compared, but only when the quantitation of the scoringwas used for further analyses. Representative examples
showing the range of staining intensity in these studies system was identical (for example, adventitial angiogen-
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Fig. 2. Scoring scale for angiogenesis (mi-
crovessel formation). (a) (vWF 3300, neoin-
tima) A single microvessel (score 5 11). (b)
(vWF 3300, neointima) A few scattered mi-
crovessels (score 21). (c) (vWF 3300, adven-
titia) A large number of microvessels (score
31). (d) (vWF 3300, adventitia) Density of
microvessels needed to have a score of 41.
Fig. 3. Normal vein. (a) Note the thin one-
to two-layer intima (thin arrows) and three-
to four-layer media (thick arrows) of normal
vein (hematoxylin and eosin 3400). (b) Rela-
tive absence of endothelial cell staining in the
adventitia and media of normal vein. Note the
intense staining of the single layer endothe-
lium (vWF 31500). (c) Thickness of normal
venous (between thin arrows, V) and arterial
(double-headed arrow, A) intima media (SMA
3117). (d) Thickness of the venous neointima
and media in a dialysis patient with venous
stenosis (SMA 3117). At an identical magnifi-
cation to (c), the venous neointima (d; double-
headed arrow, N) is 20 times thicker than the
intima media of normal vein (c; between thin
arrows). Also, note that the venous media (d;
M, length of bar) is as thick as the arterial
media in (c), indicating arterialization of the
vein.
esis was compared with neointimal angiogenesis, because the one cell-layer-thick intima (thin arrows) and the three
a score of 21 at either of these sites indicates the same to four cell-layer-thick media (thick arrows; Table 2).
number of microvessels). Comparisons were never made Cellular phenotypes. (1) SMA was present in the me-
when the scoring system for the parameters was not dia of normal vein (between thin arrows, Fig. 3c). (2)
the same (for example, PDGF in adventitial vessels was vWF was expressed by the endothelial cell layer (Fig.
never compared to bFGF in adventitial vessels, as a score 3b) and occasionally by vessels within the adventitia.
of 21 for bFGF indicates a different level of staining as (3) There were no Ki-67–positive proliferating cells in
compared with a 21 score for PDGF). Statistical analy- normal vein. (4) Macrophages were rarely present within
ses were performed using analysis of variance (ANOVA the adventitia of normal vein. (5) Desmin was present
with Tukey’s test, SigmaPlot). A P value of ,0.05 was
within the venous media only. Also note the pronouncedconsidered significant.
difference in size between normal vein and the samples
from dialysis patients with venous stenosis (Fig. 3 c com-
RESULTS pared with d).
Normal vein Cytokines. (1) bFGF was present within the venous
media and intima. (2) PDGF was present within theHematoxylin and eosin. Normal vein of a similar cali-
ber to our stenotic samples is shown in Figure 3a. Note venous media. (3) VEGF was present within the venous
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Table 2. Different expression of cell types, cytokines and matrix Downstream (proximal) vein (H and E). As for the
proteins in the upstream graft and downstream vein
sections that contained PTFE graft, a number of distinct
Stenosed Stenosed Normal layers were present in the downstream vein (Fig. 4b),
Parameter graft vein vein with the obvious exception of PTFE graft material and
Cell types the associated macrophage/giant cell layer. These in-
H/E neointimaa 1.8960.35 3.8060.37 0
cluded (1) a true adventitia with significant vascularity;SMA neointimaa 2.0060.31 4.0060.37 0
Desmin neointimab 0.3360.17 1.1160.42 0 (2) a thickened venous media; and (3) significant venous
Mø adventitiab 2.0060.62 1.3360.42 1 neointimal hyperplasia (mean expression score 3.80 6
Mø neointima 2.5060.50 2.0060.45 0
0.37), which was made up of smooth muscle cells/myofi-vWF neointima 1.2960.42c 1.8060.58 0
vWF adventitia 2.8660.34c 2.6060.25 1 broblasts, ECM components, and microvessels.
Ki-67 adventitia 2.1360.48 0.8360.31 0
Ki-67 neointima 2.0060.38 1.1760.31 0 Cellular phenotypes (Table 2)
Cytokines
bFGF adventitia (ves.) 2.2560.37 2.4060.40 0 a-Smooth muscle actin. This was present mainly in the
bFGF neointima (stromal)b 2.1460.40 1.4060.40 0 region of VNH, both in the downstream vein (4.00 6
bFGF neointima (ves.)b 2.5760.48 1.8060.49 0
0.41; Fig. 3d) and in the setting of upstream PTFE graftPDGF adventitia (ves.) 1.8860.39 2.1760.48 0
PDGF neointima (stromal)b 1.8860.52 3.0060.32 0 (2.00 6 0.81). Surprisingly, double-labeling studies for
PDGF neointima (ves.)b 1.5060.33 2.8060.66 0 SMA and Ki-67 indicated that, at least at the time of
VEGF adventitia (ves.)b 3.0060.42 4.0060.71 1
sampling, the vast majority of SMA-positive cells in someVEGF neointima (stromal) 2.7160.42 2.5060.29 0
VEGF neointima (ves.) 3.3360.42 3.560.87 0 samples were not actively proliferating (Fig. 4f). The
Matrix proteins media of downstream vein were strongly positive for
Tenascin adventitia (ves.) 2.0060.84 2.2560.48 2
SMA (Fig. 3d).Tenascin neointima 3.2060.20 2.7560.25 0
Collagen adventitia (ves.)b 2.5060.87 3.2060.20 3 Desmin. There was strong expression of desmin within
Collagen neointima 3.0060.45 3.0060.00 0 the venous media (5.00 6 0.00) and occasionally on the
Collagen neointima (ves.) 3.0060.58 3.0060.58 0
abluminal side of the neointima in both downstream veinFN adventitia (ves.)b 3.3360.49 4.1760.40 4
FN neointima (stromal)b 4.0060.22 3.4060.87 1 (1.11 6 0.42) and upstream graft (0.33 6 0.17).
FN neointima (ves.)b 4.8660.14 3.5061.19 0 Macrophages. Maximal macrophage (M f ) infiltration
Laminin adventitia (ves.) 3.8860.13 3.6760.21 2
was in the area of the macrophage/giant cell reaction,Laminin neointima 2.4360.30 2.6760.33 0
Laminin adventitia (ves.) 3.6760.21 3.6760.33 0 layering both sides of the graft (Fig. 4 e, g). In addition,
Mf were also present in smaller numbers within theAbbreviations are defined in Appendix.
a Statistically significant differences actual graft material and within the adventitia (upstream
b .0.5 separation in score indicating a possible trend
graft 5 2.00 6 0.62, downstream vein 5 1.33 6 0.42)c Statistically significant difference between two non-identical parameters
and neointima (upstream graft 5 2.5 6 0.50, downstream
vein 5 2.0 6 0.45).
von Willebrand factor (endothelial cells). This endo-
media and intima on smooth muscle cells and endothelial thelial cell marker identified microvessels, both within
cells. the adventitia (upstream graft 5 2.86 6 0.34, down-
Matrix proteins. Tenascin, collagen IV, and fibronec- stream vein 5 2.60 6 0.25) and neointima (upstream
tin were present within adventitial vessels in normal vein. graft 5 1.29 6 0.42, downstream vein 5 1.80 6 0.58;
Fibronectin was also present within the intima of normal Fig. 4 c, d).
vein. Ki-67 (proliferating cells). The largest number of Ki
67-positive cells were in areas of microvessel formation
Venous stenosis specimens (Table 2) (on endothelial and smooth muscle cells) within the ad-
Upstream PTFE graft (H and E). A number of distinct ventitia (upstream graft 5 2.13 6 0.48, downstream vein 5
layers were visible on these sections (Fig. 4a). These 2.60 6 0.25). Ki-67–positive cells were also present within
included: (1) a false adventitia on the outside of the stromal-type cells in the neointima (upstream graft 5
graft that often had very prominent angiogenesis; (2) a 2.00 6 0.38, downstream vein 5 1.17 6 0.31; Fig. 4 d, f).
macrophage and foreign body giant cell layer on both Some microvessels within the neointima demonstrated
the adventitial and luminal sides of the PTFE graft; (3) active angiogenesis (identified by double-labeling studies
PTFE graft material infiltrated by occasional mononu- for Ki-67 and vWF; Fig. 4d).
clear cells; (4) a prominent region of venous neointimal
Cytokines (Table 2)hyperplasia (extent of arrow in Fig. 4a; mean score 6
SEM 5 1.89 6 0.35) comprising smooth muscle cells and Basic fibroblast growth factor. bFGF was present on
myofibroblasts, ECM components, and a large number neointimal stromal (smooth muscle cells/myofibroblasts)-
of microvessels; and finally (5) in many cases, an endo- type cells (upstream graft 5 2.14 6 0.40, downstream
vein 5 1.40 6 0.40) and neointimal microvessels (up-thelial layer that lined the neointima.
Fig. 4. Cell types and cytokines (adventitia
to left and lumen to right). (a) PTFE graft
(hematoxylin and eosin 3200). Note the sig-
nificant venous neointimal hyperplasia (extent
of arrow) between the graft (G) and the lumen
(L). (b) Downstream vein (hematoxylin and
eosin 3200). Note the presence of microves-
sels (thin arrows) within the adventitia (A).
Also note the thickened (arterialized) media
(M, double-headed arrow) and the significant
amount of neointimal hyperplasia (N, bar).
(c) Downstream vein; neointima (vWf 3400).
Note the prominent angiogenesis within the
neointima (arrows), as assessed by this endo-
thelial cell marker (d) downstream vein; neo-
intima (vWF 1 Ki67 3800). High-power view
of a microvessel within the neointima of down-
stream vein. Note the distinct colocalization of
blue (endothelial) and brown (proliferating)
cells indicating active endothelial cell prolifer-
ation (angiogenesis). (e) Upstream graft; neo-
intima (PG-M1 32000). High-power view of
a macrophage giant cell adjacent to the neo-
intimal surface of PTFE graft (G). Also note
the large number of macrophages in this area
(thin arrows). ( f ) Downstream vein; neo-
intima (SMA 1 Ki-67 31000). High-power
view of a portion of the neointima stained for
smooth muscle cells (brown) and proliferating
cells (blue). Note that almost all the active
cellular proliferation in this specimen (arrows)
is occurring within the neointimal microvessels
(angiogenesis). At the time that this specimen
was harvested, there was no ongoing smooth
muscle cell proliferation (g) PTFE graft; ad-
ventitia (bFGF 3500). Note the strong expres-
sion of bFGF in adventitial vessels (thick arrow)
and by the macrophage giant cell layer (thin
arrow) lining the graft. (f) Downstream vein;
media and neointima (PDGF 3400). There is
strong expression of this cytokine in the ve-
nous media (M) and by smooth muscle cells/
myofibroblasts within the neointima (N, bar).
Fig. 5. Matrix and structural proteins. (a)
PTFE graft (tenascin 3200). There is strong
expression of tenascin in the region of the
macrophage giant cell layer (thin arrow) sur-
rounding PTFE graft (G) and on the ablumi-
nal side of the neointima (thick arrow). (b)
PTFE graft (collagen IV 3160). Collagen is
present as expected within the walls of promi-
nent adventitial blood vessels (thin arrows)
and in this particular sample within the lumi-
nal portion of the neointima (thick arrow).
(c) Downstream vein; neointima (fibronectin
3500). There is strong diffuse expression of
fibronectin by ECM components. (d) Down-
stream vein; neointima (laminin 3500). Lami-
nin is a prominent component of microvessels
(arrows) within the neointima.
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stream graft 5 2.57 6 0.48, downstream vein 5 1.80 6 present on stromal-type cells (upstream graft 5 4.00 6
0.22; downstream vein 5 3.40 6 0.87, Fig. 5c) and mi-0.4). bFGF was also present on the adventitial vessels
overlying both upstream graft (2.25 6 0.37; Fig. 4g) and crovessels (upstream graft 5 4.86 6 0.14; downstream
vein 5 3.50 6 1.19) within the neointima. Fibronectindownstream vein (2.40 6 0.40). There was intense stain-
ing for bFGF by the macrophage giant cell layer lining was present on the macrophage and foreign body giant
cell layer lining upstream graft (1.5 6 0.96) and alsoboth sides of the graft (3.13 6 0.30; Fig. 4g) and by
infiltrating mononuclear cells within the graft (3.17 6 appeared to be secreted into the actual matrix of the
graft material.0.40). In some samples, the PTFE graft itself stained
strongly for bFGF (Fig. 4g), suggesting that this cytokine Laminin. Laminin was expressed by adventitial ves-
sels in both upstream graft (3.88 6 0.13) and downstreammight be diffusing through the interstices of the graft.
Platelet-derived growth factor. PDGF was present in vein (3.67 6 0.21; Fig. 5d). Laminin was present within
the neointima of upstream graft (2.43 6 0.30) and down-adventitial vessels in both upstream graft (1.88 6 0.40)
and downstream vein (2.17 6 0.48). There was strong stream vein (2.67 6 0.33), and in microvessels within the
neointima (upstream graft 5 3.67 6 0.21, downstreamstaining for PDGF by the macrophage giant cell layer on
both sides of the graft (2.38 6 0.42) and by macrophages vein 5 3.67 6 0.33). Laminin was also present in stromal
elements of the neointima, especially at the site of whatthat had infiltrated into the graft material (1.50 6 0.54).
Within the region of VNH, PDGF was present on stro- appeared to be needle track injuries.
mal cells (upstream graft 5 1.88 6 0.52; downstream
Statistical analysesvein 5 3.00 6 0.71; Fig. 4h) and microvessels (upstream
Quantitative results are presented in Table 2. VNHgraft 5 1.50 6 0.33; downstream vein 5 2.80 6 1.48).
was more pronounced in downstream vein as comparedVascular endothelial growth factor. VEGF was pres-
with upstream graft by hematoxylon and eosin analysisent in the adventitial vasculature overlying both up-
(P 5 0.005). Within this downstream lesion, there wasstream graft (3.00 6 0.42) and downstream vein (4.00 6
greater expression of the smooth muscle cell marker0.71). VEGF was also present in the macrophage/giant
SMA actin as compared with upstream graft (P 5 0.004).cell layer lining both sides of the graft (2.75 6 0.56)
Finally, there was significantly more angiogenesis in theand in macrophages that had infiltrated into the graft
adventitia of upstream graft as compared with the neo-material. As for bFGF and PDGF, VEGF was present
intima at the same site (P 5 0.038; Table 2).in stromal-type cells (upstream graft 5 2.71 6 0.42;
Because of the small number of samples available, wedownstream vein 5 2.50 6 0.30) and microvessels (up-
could have missed important differences as a result ofstream graft 5 3.33 6 0.42; downstream vein 5 3.50 6
inadequate power. Therefore, possible trends were iden-0.87) within the venous neointima.
tified (mean separation .0.5) toward differences between
Matrix and structural proteins (Table 2) the upstream graft and downstream vein (Table 2). A
brief summary of these trends between upstream graftTenascin. Tenascin was present within adventitial ves-
sels overlying both upstream graft (2.00 6 0.84) and down- and downstream vein is given below.
Cellular phenotypes. Desmin had stronger expressionstream vein (2.25 6 0.48; Fig. 5a). Tenascin appeared to
be secreted by the macrophage/giant cell layer lining on the abluminal side of downstream vein as compared
with downstream graft. Macrophages were generallyboth sides of the graft. Within the neointima, tenascin
was present within the ECM in upstream graft (3.20 6 more prominent within the adventitia of upstream graft.
Ki-67 (proliferating cells) were present in the greatest0.20) and downstream vein (2.75 6 0.48). While the ex-
pression of tenascin appeared to be more on the ablumi- numbers in the adventitia and neointima of the upstream
graft as compared with the downstream vein. There werenal surface in some samples (Fig. 5a), this was not consis-
tent throughout the study. Tenascin was also expressed relatively more microvessels in the neointima of down-
stream vein as compared to upstream graft.by microvessels within the neointima. The hypertrophied
venous media had strong expression of tenascin (3.25 6 Cytokines. bFGF was increased within the neointima
(stromal cells and microvessels) of upstream graft as0.63).
Collagen IV. Collagen IV was expressed by adventitial compared with downstream vein. PDGF, in contrast,
was increased within the neointima (stromal cells andvessels in both upstream graft (2.50 6 0.87) and down-
stream vein (3.20 6 0.20; Fig. 5b). Collagen IV was also microvessels) of downstream vein. VEGF was increased
in the adventitial vessels of downstream vein as com-present within the neointima of upstream graft (3.00 6
0.45) and downstream vein (3.00 6 0.00) and in microves- pared with those of upstream graft.
Matrix and structural proteins. Fibronectin was in-sels within the neointima (upstream graft 5 3.00 6 0.58;
downstream vein 5 3.00 6 0.58). creased in the adventitial vessels of downstream vein and
within the neointima (stromal cells and microvessels) ofFibronectin. Fibronectin was expressed by adventitial
vessels in both upstream graft (3.33 6 0.49) and down- upstream graft. Collagen was increased in the adventitial
vessels of downstream vein.stream vein (4.17 6 0.40; Fig. 5c). Fibronectin was also
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DISCUSSION within the intima of our samples at an earlier time point
has gone unrecognized by the present study. While ap-Despite the clinical importance of hemodialysis vascu-
proximately 50 to 75% of stromal-type cells within thelar access dysfunction, there has been little research on
neointima were positive for SMA, this was not the casethe pathogenesis of venous neointimal hyperplasia in the
for desmin, which was present on less than 10% of neo-specific setting of dialysis access grafts. Therefore, the
intimal cells (mainly at the abluminal border). In theirexpression of specific cell types, cytokines, and matrix
model of coronary venous grafting, Shi et al [18] andproteins in dialysis access specimens with venous stenosis
O’Brien et al [19] have suggested that SMA-positive,were documented in an attempt to understand better
desmin-negative cells are likely to be adventitial fibro-the pathogenesis of this lesion. We believe that this is
blasts that have transformed into smooth muscle-typea first step toward the development of more effective
cells and have migrated into the neointima. This is anmeasures for the prevention and treatment of this condi-
important concept as it suggests that the changes in thetion.
adventitia could be influencing final luminal stenosis (dis-
cussed later in this article). We plan on closely examiningInitiating events
this theory in a large animal model of VNH (abstract;An important initiating event in the pathogenesis of
Roy-Chaudhury et al, J Am Soc Nephrol 9:181, 1998).VNH is thought to be hemodynamic stress (specifically
a low shear stress [23, 24] caused by turbulence and Adventitial remodeling
compliance mismatch), which then activates (alters the
This study clearly documents the presence of cellularphenotype of) smooth muscle cells and endothelial cells
proliferation, ECM protein accumulation, and cytokine[25] at the graft-vein anastomosis. Our study suggests a
expression within the adventitia of both upstream graftsecond potential initiating factor, namely the macro-
and downstream vein. In particular, there was increasedphage giant cell layer that lines both sides of PTFE graft
microvessel formation in the adventitia surrounding up-and has intense expression of all three cytokines dis-
stream graft as compared with the neointima at the samecussed in this article (especially bFGF; Fig. 4g). We be-
site. These findings are in keeping with recent studies
lieve that PTFE graft material functions as a foreign
that indicate that activation and migration of adventitial
body (perhaps made worse by the repeated punctures
cell types are an important determinant of vascular ste-
for dialysis), which attracts activated macrophages to the nosis [18, 19]. Specifically, some studies suggest that ad-
site of the lesion. These activated macrophages then verse adventitial remodeling (constriction) could be as
produce cytokines such as bFGF, PDGF, and VEGF, important as neointimal volumes in determining final
which are known to cause smooth muscle cell, fibroblast, luminal stenosis [26]. With regard to possible clinical
and endothelial cell differentiation, proliferation, and application, therefore, our study suggests that therapeu-
migration [11]. tic intervention in experimental models should be tar-
geted at both the adventitia and the neointima.Smooth muscle cell proliferation
Table 2 demonstrates the presence of active cellular Angiogenesis
proliferation within stromal-type cells in the neointima. A consistent finding in our study was the presence of
There were significantly more smooth muscle cells within microvessels, both within the neointima and adventitia
the neointima of downstream vein as compared with the of upstream graft and downstream vein (Fig. 4 c, d, f, g).
upstream graft, which suggests a preferential migration In addition, many of our specimens also had evidence
of smooth muscle cells from the venous media of the of active endothelial and pericyte proliferation (angio-
downstream vein into the neointima. Interestingly, in genesis) within microvessels in the neointima (Fig. 4 d, f)
some specimens with a large number of smooth muscle and adventitia. These results are in keeping with those
cells within the venous neointima, double-staining exper- of Rekhter et al, who demonstrated that maximal cellular
iments revealed active proliferation within endothelial proliferation occurred in vascular regions of the neoin-
cells lining microvessels (angiogenesis, discussed later in tima [10]. Of note, microvessels have also been found
this article), but not in the smooth muscle cells (Fig. 4f), within the neointima and adventitia in coronary athero-
which formed the bulk of the neointimal lesion. This sclerosis [27] and in experimental models of coronary
could be due to the fact that migration of smooth muscle stenosis [28]. The importance of neointimal and adventi-
cells from the media, rather than in situ intimal prolifera- tial angiogenesis is emphasized by recent seminal studies
tion, is the key driving force for VNH. An alternative that have demonstrated that both neoplastic [29, 30] and
explanation could be that our samples can only provide non-neoplastic [31] tissue growth can be reduced by inhib-
us with a snapshot of a single time-point that is at the iting angiogenesis. Our primarily descriptive study (which
end of the natural history of the disease process. Thus, examines tissue at a single time point only) unfortunately
does not allow a cause and effect relationship betweenit is possible that active smooth muscle cell proliferation
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angiogenesis and neointimal hyperplasia to be identified. the pathogenesis of VNH in dialysis access grafts. These
Further studies in an experimental animal model are include cellular proliferation, microvessel formation, and
needed to establish whether anti-angiogenic agents could cytokine expression (perhaps the key factor) by smooth
be an effective therapeutic modality for VNH. muscle cells, endothelial cells, and macrophages, re-
sulting in the activation and proliferation of these cell
Cytokines types. Based on the results from this study, we are cur-
Platelet-derived growth factor and bFGF are impor- rently testing specific interventions in a pig model of
tant mediators of the smooth muscle cell proliferation VNH (abstract; ibid). In conclusion, we believe that ve-
that characterizes neointimal hyperplasia in balloon an- nous stenosis in PTFE dialysis grafts could be the ideal
gioplasty models [13, 14]. bFGF and VEGF are also clinical target for novel locally delivered therapeutic in-
potent angiogenic growth factors [32]. All three cyto- terventions against neointimal hyperplasia, in view of
kines were present on smooth muscle cells and on vessels, the accessibility of both the patient (on hemodialysis
within the adventitia and neointima of upstream graft three times a week) and the lesion (superficially located).
and downstream vein in our study. There was also intense
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APPENDIXdeposition and clearance.
We believe that these three cytokines could be primar- Abbreviations used in this article are: bFGF, basic fibroblast growth
ily responsible for the smooth muscle cell and endothelial factor; FN, fibronectin; H/E, hematoxylin and eosin; Mø, macrophages;
PDGF, platelet-derived growth factor; PTFE, polytetrafluoroethylene;cell proliferation seen in our samples. bFGF and PDGF
SMA, a-smooth muscle actin; VEGF, vascular endothelial growth fac-also play an important role in the accumulation of ECM tor; VNH, venous neointimal hyperplasia; vWF, von Willebrand factor.
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